Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. - sprookjes - yvandenbroek - TriplyDB

Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q34032884

about

My approach to the treatment of scleroderma Echocardiographic findings associated with mortality ortransplant in patients with pulmonary arterial hypertension:A systematic review and meta-analysis Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management The Critical Role of Pulmonary Arterial Compliance in Pulmonary Hypertension.Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular function Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy.Structural and mechanical adaptations of right ventricle free wall myocardium to pressure overload Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry Lung involvement in systemic sclerosis.Pulmonary arterial hypertension associated with systemic sclerosis.Connective tissue disease-associated pulmonary arterial hypertension.Overview of current therapeutic approaches for pulmonary hypertension.The right ventricle in scleroderma (2013 Grover Conference Series).Right ventricular remodeling in idiopathic and scleroderma-associated pulmonary arterial hypertension: two distinct phenotypes.Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiac function, and ventricular remodeling.17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects.Bidimensional measurements of right ventricular function for prediction of survival in patients with pulmonary hypertension: comparison of reproducibility and time of analysis with volumetric cardiac magnetic resonance imaging analysis Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension Chronic hypoxia induces right heart failure in caveolin-1-/- mice.Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.A prediction model for progressive disease in systemic sclerosis Updating clinical endpoint definitions.Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis.Pulmonary hypertension complicated by pericardial effusion: a single center experience.Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension.Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension.Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era.The prognostic significance of pulmonary arterial capacitance in pulmonary arterial hypertension: single-center experience Pulmonary pulse wave transit time is associated with right ventricular-pulmonary artery coupling in pulmonary arterial hypertension.Update on pulmonary vascular diseases 2010.Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts.N-TproBNP as biomarker in systemic sclerosis.Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.Early systemic sclerosis-opportunities for treatment.Elevated Adipsin Levels are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis.

P2860

Q24618843-2601D4DC-081C-4D86-8E0D-9DF7E35E7AF6 Q26748865-4727B89B-B3AB-4D83-904B-E858583BA291 Q27023769-A4513642-FED0-4CFB-821B-0A39EF0E124F Q33772330-374F7EF2-E629-4A8F-86CA-CA6FBCD8963B Q33788474-BD41B986-25F5-4FD7-AFE5-0768F915F7AD Q33806077-231A25C5-DFD6-45CE-AF9C-99BBD9AABA5C Q33806184-1465F016-FCCC-4F22-95EC-F5187684D596 Q34106037-4B1F619D-1692-442D-9F44-21B1CD4438CC Q34559855-4065328E-C4F3-4F12-B063-1A612106DE3E Q34609902-AE2B6DE5-C8E7-454D-81D0-46402FE9540D Q34732817-89A45792-A9DB-4BFF-BBA0-DAEA265577EF Q35002423-EAEA2F44-3A09-470F-9D2F-EBD6E5390C41 Q35029607-595562A8-DBB4-431B-8A41-432B29BE4131 Q35412362-B33513EB-5F3E-442E-BC8B-FA48D9406909 Q35517421-9D2FBC50-80D3-4FB5-A4AF-0F754E119B9F Q35665758-E4BAB028-BD96-411B-9F76-41D7B50C2C7A Q35985597-FEC2DBCB-2739-40DB-B82F-96705BE7427E Q35987282-925CDCAE-2643-40B9-91FF-F3D8DBD8D66C Q36016524-DD9E021E-9411-4994-ABC9-244E28F8C8B8 Q36016546-9940BA9B-1481-42B1-B649-06D17478C0EE Q36042487-45F38049-B16E-41BF-A226-DA3CCFB4A7B8 Q36150934-235ABF56-4E96-4DE5-BD74-EE7976EB4AF7 Q36272405-3FC7D8B8-A214-448F-AAB4-F5C3701EAA28 Q36375900-F6E7F755-C9A8-4161-8137-F603D4490255 Q36810813-CF15C9B8-7FF6-4099-8B73-75B4027A1F45 Q36811779-D1883E73-DDA5-4053-931B-CB574C3D9E01 Q36916336-476BE0F9-BD34-4FBF-AA5E-D9D987AE0A45 Q37004259-EF3529D8-3F3B-4AE1-9F48-4B2A22D787FE Q37149329-5C814B40-7648-4EEC-9D24-427C34B8342F Q37200751-E68DE94D-10F9-4D7C-ABCE-F8EB65AC02F3 Q37274520-0D88D312-A414-4E1A-A3BB-BED8FFBE779B Q37345940-22B1DD51-3AD8-4F4F-839A-F15CACB22A96 Q37555416-2FAC116E-F8F4-4078-AB42-39E4BF8C13B8 Q37555462-15D9D2F0-4CE1-4862-B5A1-B40F543380EA Q37898899-4D031C25-7371-4CE8-B868-5EBEB7F19EEE Q37956146-8F78332E-DD32-4D24-959E-683FD5E9EFBF Q38016375-3C573D2F-A59E-4173-B093-EBE67A5EFA84 Q38112387-3B628918-DF8A-4AD3-A8F1-D032C947387D Q38364855-F139CEDD-7488-41E3-9511-39CD31EAAA9A Q38708686-7625146E-462E-4405-AA2B-17D3E59C90DF

P2860

Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q34032884

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Hemodynamic predictors of surv ...... lmonary arterial hypertension.

@ast

Hemodynamic predictors of surv ...... lmonary arterial hypertension.

@en

Hemodynamic predictors of surv ...... lmonary arterial hypertension.

@nl

type

label

Hemodynamic predictors of surv ...... lmonary arterial hypertension.

@ast

Hemodynamic predictors of surv ...... lmonary arterial hypertension.

@en

Hemodynamic predictors of surv ...... lmonary arterial hypertension.

@nl

prefLabel

Hemodynamic predictors of surv ...... lmonary arterial hypertension.

@ast

Hemodynamic predictors of surv ...... lmonary arterial hypertension.

@en

Hemodynamic predictors of surv ...... lmonary arterial hypertension.

@nl

P1433

Q34032884-6C5F8E95-29F7-4E0E-AA23-F62AE58FB32F

P1476

Q34032884-90E31855-25E6-41B2-9F10-40005043E140

P2093

Q34032884-081D99FD-2CBA-41F1-9029-62026C332C6C

Q34032884-150E600F-008F-4A81-BA1F-E9614F72326B

Q34032884-4B1D42F6-4C07-4505-B42E-ABBC4B07F90F

Q34032884-597AFF3A-BE9E-4F42-827E-2F63B936AA72

Q34032884-775C5AD0-9634-49FC-895A-EB839A6A8863

Q34032884-7BF62914-4E64-412B-8865-D534C4C16A5E

Q34032884-912C3130-B4A8-4DA7-84F4-4D171FE8C320

Q34032884-92C9600C-5226-4A57-8E31-C0C75D11F383

Q34032884-9E99D73D-8E61-483A-9C54-646083A93CEC

P2860

Q34032884-04C5B217-77A6-417B-B9F4-201C5F51CA42

Q34032884-0E1D19FB-A1A1-473F-94B6-E630406E4189

Q34032884-0EF156A6-B2CF-41CB-9DE9-5BAB2EA4F748

Q34032884-284A28A2-16F2-40EB-A434-720D9AAC2A1C

Q34032884-2ECCF8DA-EBCD-42D7-B15F-D78D064FA183

Q34032884-48E481D2-B6B0-4983-8BD9-48662D7A7F44

Q34032884-4BD76263-14BF-411C-9FCD-AF41299CDA10

Q34032884-65452BAB-E0F5-499D-8DE2-0275E7729CD0

Q34032884-6647F455-8AA0-4195-B76A-4B52A91C4592

Q34032884-71532E99-1BBF-41CE-B4AC-A60057AB5F5E

P304

Q34032884-F254E14D-0ED0-4F60-B313-140AF5FA6AF2

P31

Q34032884-9A8584AD-606F-4F4B-BACA-2FC1164CBB04

P356

Q34032884-457CD78B-A2E5-431B-9D0F-D5C7917D00AB

P407

Q34032884-45C10031-D899-475D-AF51-254CE7716AE0

P433

Q34032884-43969A30-FA07-4119-9234-45B50291DE20

P478

Q34032884-A0D67564-3A2C-46FD-8641-9E6381FD43AD

P50

Q34032884-23CD284B-3EE2-4842-A279-11FCDB85EBAA

Q34032884-5B3921D3-F837-48D6-8DE8-7EF9B4B7DD51

Q34032884-82BE5F92-87C0-4E0B-9291-EEF3F969220A

P577

Q34032884-BD66F35E-E669-4DFA-B6AC-FBD650357F27

P698

Q34032884-1694E598-1F30-40B9-8F64-C71BA3C94D45

P921

Q34032884-DF9E0F33-7CAE-4ADA-ABEB-54B9A8C3152A

P932

Q34032884-A48BF1F8-94B8-42E1-9CA6-76794F69E6D0

P356

RCCM.200912-1820OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension

@en

P2093

Ari L Zaiman

http://www.w3.org/2001/XMLSchema#string

Danielle Boyce

http://www.w3.org/2001/XMLSchema#string

Fredrick M Wigley

http://www.w3.org/2001/XMLSchema#string

Hunter C Champion

http://www.w3.org/2001/XMLSchema#string

Noah Lechtzin

http://www.w3.org/2001/XMLSchema#string

Paul M Hassoun

http://www.w3.org/2001/XMLSchema#string

Reda E Girgis

http://www.w3.org/2001/XMLSchema#string

Stephen C Mathai

http://www.w3.org/2001/XMLSchema#string

Traci Housten

http://www.w3.org/2001/XMLSchema#string

P2860

Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

Clinical classification of pulmonary hypertension.

Mortality in systemic sclerosis: an international meta-analysis of individual patient data.

Determinants of right ventricular ejection fraction in pulmonary arterial hypertension.

Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.

End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives.

Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Changes in causes of death in systemic sclerosis, 1972-2002

P304

252-260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200912-1820OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P50

Jérôme Le Pavec

Laura K. Hummers

P577

2010-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20339143

http://www.w3.org/2001/XMLSchema#string

P921

P932

2913238

http://www.w3.org/2001/XMLSchema#string